CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
4.540
+0.430 (10.46%)
At close: Mar 9, 2026, 4:00 PM EDT
4.840
+0.300 (6.61%)
After-hours: Mar 9, 2026, 4:16 PM EDT
CervoMed Employees
CervoMed had 15 employees as of December 31, 2024. The number of employees increased by 7 or 87.50% compared to the previous year.
Employees
15
Change (1Y)
7
Growth (1Y)
87.50%
Revenue / Employee
$410,652
Profits / Employee
-$1,705,666
Market Cap
41.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 64 |
| Atara Biotherapeutics | 38 |
| Jasper Therapeutics | 27 |
| Lisata Therapeutics | 26 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| Veru Inc. | 20 |
| Sensei Biotherapeutics | 15 |
CRVO News
- 5 days ago - CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 20 days ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 3 months ago - CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 3 months ago - CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 5 months ago - CervoMed to Present at the Emerging Growth Conference - GlobeNewsWire
- 5 months ago - CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - Benzinga
- 5 months ago - CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies - GlobeNewsWire